Mangoceuticals, Inc. disclosed in its latest 10-Q filing that it is at risk of Nasdaq delisting due to a sustained stock price below $1.00 per share, with an August 3, 2026 deadline to regain compliance. The company’s liquidity is constrained, with current assets of approximately $212K against liabilities exceeding $737K as of March 31, 2026. Its business hinges on compounded pharmaceuticals produced through a related-party arrangement with Epiq Scripts, LLC, operating under FDA Section 503A exemptions. Increasing FDA scrutiny of compounding practices and telehealth prescribing models raise regulatory risks. Growth initiatives include intellectual property acquisitions and telehealth-enabled wellness brands, but ongoing net losses and operational dependencies on related parties underscore financial and execution risks. Mangoceuticals must address near-term capital needs and regulatory compliance to sustain operations and market presence.